C
LIVE

Serial Number

77212184

Owner

ROCHE DIAGNOSTICS GMBH

Attorney

Mona Gupta

Filing Date

Jun 21, 2007

Add to watchlist:

No watchlists yet
View on USPTO

C Trademark

Serial Number: 77212184 • Registration: 3849207

C is a trademark filed by ROCHE DIAGNOSTICS GMBH on June 21, 2007. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

ROCHE DIAGNOSTICS GMBH (552 trademarks)

MANNHEIM 68305 , DE

Entity Type: 16

MTM Laboratories AG (7 trademarks)

Im Neuenheimer Feld 583
Heidelberg 69120 , DE

Entity Type: 03

ROCHE MTM LABORATORIES AG (7 trademarks)

IM NEUENHEIMER FELD 583
HEIDELBERG 69120 , DE

Entity Type: 03

Trademark Details

Filing Date

June 21, 2007

Registration Date

September 21, 2010

Published for Opposition

November 17, 2009

Goods & Services

Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds; medical diagnostic reagents and kits comprised of medical diagnostic reagents and assays for detection of cancer and neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the detection of premalignant and malignant cancerous conditions, cancer and inborn errors; medical diagnostic preparations, namely, in-vitro and in-vivo diagnostic test kits, diagnostic immunocytochemical kits, diagnostic immunohistochemical kits, diagnostic histology kits, diagnostic cytology kits, diagnostic liquid-immuno-assay kits, diagnostic solid-phase immuno-assay kits, diagnostic strip-tests, diagnostic dip-stick-tests, point of care tests, diagnostic lateral-flow assay kits, diagnostic flow-through assay kits, diagnostic immuno-chromatographic kits, all of the above-mentioned kits being for use in early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases; medical diagnostic test strips and diagnostic dip-stick tests for use in early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases

Chemicals used in industry and science, diagnostic preparations, reagents and chemical test kits comprised of reagents for chemical analyses and reagents for medical research use for detection of cancerous conditions, neoplastic conditions, inflammatory conditions, infectious conditions, degenerative conditions, genetically aberrant or diseased conditions, proliferatively aberrant or diseased conditions, vascular disease conditions, premalignant conditions, malignant conditions, cancer and inborn errors for scientific or research use

Medical services, veterinary services, medical diagnostic services and provision of medical diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary diagnostic services and provision of veterinary diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds

[ Diagnostic testing machines, namely, point-of-care testing machines, diagnostic liquid-immuno-assay machines, diagnostic immunocytochemical machines, diagnostic immunohistochemical machines, diagnostic histology machines, diagnostic cytology machines, diagnostic solid-phase immuno assay machines, diagnostic ELISA testing machines, diagnostic immuno-chromatographic machines, all of the aforementioned machines being used to analyze and/or provide diagnostic test results and used in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious and genetic diseases associated with cancer, proliferative diseases associated with neoplastics and dysplastic conditions or vascular diseases as indicated above; medical diagnostic equipment, namely, containers specially designed for storing and transporting medical samples in the nature of tubes, multiwell plates, columns, strips, sticks, brushes, all for sampling of medical samples from body cavities and epithelia; medical syringes, needles for medical use, spatulas for medical samples and medical diagnostic testing, and medical diagnostic testing swabs, cloths, tampons, all for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative and vascular diseases as indicated above; diagnostic nucleic acid detection machines, diagnostic nucleic acid amplification machines, diagnostic immuno-histology machines and diagnostic immuno-cytology machines all used to analyze and/or provide diagnostic test results and used in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious and genetic diseases associated with cancer, proliferative diseases associated with neoplastics and dysplastic conditions or vascular diseases as indicated above; medical diagnostic apparatuses and instruments, namely, hand-held, table-top and floor-standing centrifugal, gravitational-separating, electrophoretic, chromatographic, conductometric, potentiometric, spectrometric, spectro-photometric, radiologic electromagnetic-resonance, histological, microscopic and in-vivo-imaging machines and apparatuses for use in preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative and vascular diseases as indicated above for clinical and medical laboratory use ]

[ Scientific and technological services and research and design relating thereto, industrial analysis and research services, design and development of computer hardware and software, scientific analysis in the fields of chemistry, biology and molecular biology, laboratory research in the field of molecular biology; laboratory research in the fields of pharmaceutics and food technology; providing research in the fields of pharmaceutical, chemical and diagnostic research; research and development of pharmaceutical products and substances for others; scientific research in the nature of scientific information research services; chemical, biological, molecular biology and pharmacogenomic analysis services ]

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 25, 2024 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 13, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 13, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Sep 13, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 13, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 13, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 9, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 9, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 9, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 9, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 9, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 9, 2020 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 5, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 5, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 5, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 5, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 5, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 5, 2020 COAR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 10, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 10, 2019 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Oct 4, 2019 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Oct 4, 2019 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Oct 4, 2019 89AG
TEAS SECTION 8 & 9 RECEIVED
Oct 2, 2019 E89R
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 2, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 2, 2019 REAP
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sep 21, 2019 REM2
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 10, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 10, 2019 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
May 6, 2017 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
May 6, 2017 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 5, 2017 APRE
TEAS SECTION 8 & 15 RECEIVED
Mar 20, 2017 E815
WITHDRAWAL OF ATTORNEY GRANTED
Mar 24, 2014 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Mar 24, 2014 WOAR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 20, 2012 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 20, 2012 REAP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 18, 2012 ASGN
REGISTERED-PRINCIPAL REGISTER
Sep 21, 2010 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Aug 14, 2010 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 10, 2010 AITU
NOTICE OF ALLOWANCE CANCELLED
Aug 9, 2010 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Aug 9, 2010 D1BR
NOA MAILED - SOU REQUIRED FROM APPLICANT
Feb 9, 2010 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 17, 2009 NPUB
PUBLISHED FOR OPPOSITION
Nov 17, 2009 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 9, 2009 PREV
ASSIGNED TO LIE
Oct 7, 2009 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 6, 2009 CNSA
DATA MODIFICATION COMPLETED
Oct 6, 2009 DMCC
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 4, 2009 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 4, 2009 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 2, 2009 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2009 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 30, 2009 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Mar 31, 2009 GNS2
INQUIRY TO SUSPENSION E-MAILED
Mar 31, 2009 GNSI
SUSPENSION INQUIRY WRITTEN
Mar 31, 2009 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Mar 31, 2009 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 29, 2008 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 29, 2008 GNSL
SUSPENSION LETTER WRITTEN
Sep 29, 2008 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 6, 2008 TEME
ASSIGNED TO LIE
May 6, 2008 ALIE
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2008 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 4, 2007 GNRN
NON-FINAL ACTION E-MAILED
Nov 4, 2007 GNRT
NON-FINAL ACTION WRITTEN
Nov 4, 2007 CNRT
ASSIGNED TO EXAMINER
Sep 24, 2007 DOCK
NOTICE OF DESIGN SEARCH CODE MAILED
Jun 26, 2007 MDSC
NEW APPLICATION ENTERED
Jun 25, 2007 NWAP